Alphatec secured exclusive U.S. rights to Theradaptive’s OsteoAdapt bone graft platform through a new partnership, according to a Jan. 12 news release.
Under the agreement Alphatec can market and distribute OsteoAdapt, a bone graft for spinal fusion, in the U.S. OsteoAdapt is an osteoinductive bone graft and is being evaluated in clinical trials for spine and dental use.
Theradaptive also launched a series B financing round to support clinical studies and scaling of OsteoAdapt.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
